Theriva shareholders approve 8.9x stock plan share increase and 25x authorized share increase.

Theriva Biologics, Inc.

Stockholders approved Amendment No. 2 to the 2020 Stock Incentive Plan, increasing the share reserve from 280,000 to 2,500,000 shares.
Non-employee director annual grant limit raised from 40,000 to 250,000 shares under the amended plan.
Certificate of Change filed to increase authorized common shares from 14,000,000 to 350,000,000, effective November 1, 2024.
All four director nominees elected; BDO USA, P.C. ratified as independent auditor for FY2024.
Shareholders also approved the adjournment proposal, but it was not needed as quorum was present.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.